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CHAPTER -1 
 
 
      INTRODUCTION 
 
 
 
            Chemistry is a very broad subject, and can justly claim to encompass 
many aspects of the study of biological molecules. To most researchers in the 
cancer fields, the term ‘chemistry’ is often used in a much narrower way and is 
synonymous with the synthetic chemistry as a tool for the discovery of anticancer 
drugs. 
 
1.1.    PHARMACEUTICALCHEMISTRY 
 
 
 Pharmaceutical Chemistry is an area of chemistry that deals with the structure, 
properties and reactions of compounds that contains carbon. Chemists in general 
and organic chemists in particular can create new molecules never before proposed 
which, if carefully designed, may have important properties for the betterment of 
the human experience. One of the main objectives of organic and medicinal 
chemistry is the design, synthesis and production of molecule having value as 
human therapeutic agents1. 
 
The department of pharmaceutical chemistry is to impart in depth knowledge 
about all the chemical aspects of drugs and natural products, such as the structure, 
synthesis, isolation and structural activity relationship with the pharmacological 
activity. 
 
Medicinal chemistry 
 
 
Medicinal chemistry and bioorganic chemistry is concerned with the design, 
synthesis and analysis of the relationship between molecular structure and biological 
activity for compounds that can be used for the care or treatment of disease2-8. 
         In medicinal chemistry, the chemist attempts to design and synthesis a medicine 
or pharmaceutical agent which will benefit humanity.  Such a compound could be 
called as a ‘drug’. 
Medicinal chemistry is a part of pharmaceutical chemistry. Medicinal 
chemistry is discipline at the intersection of chemistry and pharmacology involved 
with designing, synthesizing and developing pharmaceutical drugs. Medicinal 
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chemistry involves the identification, synthesis and development of new chemical 
entities suitable for therapeutic use. It also includes the study of existing drugs, their 
biological properties and their quantitative structure activity relationship (QSAR). 
 
Medicinal chemistry is the application of chemical research techniques to the 
synthesis of pharmaceuticals. During the early stages of medicinal chemistry 
development, scientist were primarily concern with the isolation of the medicinal 
agents founds in plants. Today, scientists in this field are also equally concerned with 
creation of new synthetic drug compounds. Medicinal chemistry almost always 
geared towards drug discovery and development. 
 
The first step is pharmaceutical focused on quality aspects of medicines and 
aims to assure fitness for the purpose of medicinal products. Medicinal chemistry is a 
highly interdisciplinary science combining organic chemistry with biochemistry, 
computational chemistry, pharmacology, pharmacognosy, molecular biology, 
statistics and physical chemistry.The second step of drug discovery involves the 
synthetic modification of the hits in order to improve the biological properties of the 
compound pharmacophore. 
 
 Heterocyclic chemistry9-15 is the chemistry branch dealing exclusively with 
synthesis, properties and application of heterocyclic. Heterocyclic compound is an 
organic compound that contains a ring structure containing atom in addition to 
carbon, such as sulfur, oxygen or nitrogen as part of the ring. They may be either 
simple aromatic or non-aromatic rings. Some heterocyclic compounds are known as 
carcinogens. Researchers have show that heterocyclic amines are the 
Carcinogenic chemicals.    
   A heterocyclic compound is one which possesses a cyclic structure with at 
least two different kinds of hetero atoms in the ring. Nitrogen, oxygen and sulphur are 
most common hetero atoms. Heterocyclic compounds are very widely distributed in 
nature and are essential to life in various ways. 
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       1.2. THIAZOLIDINONE 
Thiazolidin-4-one16-19 occurs as yellow crystal and odorless. It is soluble in 
water, ethanol and solvent ether. Tetra hydro derivative of thiazole ring is known as 
thiazolidine25,26. 
NH
S
O
                  
NH
S
O
                          
NH
S
O  
Thiazolidin-5-one         Thiazolidin-4-one             Thiazolidin-2-one 
            Thiazolidin-4-one  and  its derivatives  have  high  pharmacological relevance  
since  they  are  available  in  both  natural  products and  Pharmaceutical  compounds20-25.   
Method of preparation  
The number of methods for the synthesis of thiazolidinones is widely reported in 
the literature. The main synthetic routes to thiazolidin-4-ones comprising three components 
such as an amine, a carbonyl group and mercapto acid. The classical method of synthesis 
reported may be either a one-pot three-component condensation method or a two-step 
process. The reaction starts by formation of an imine which undergoes attack by sulfur 
nucleophile, followed by intramolecular cyclization to eliminate water27. 
Kozlov co-workers33 reported a one-step cyclization reaction where in the reaction 
of ethyl 5-phenyl thioureido-3-imidazole-4-carboxylate with bromoacetic acid gives an 
imidazolylimino thiazolidin-4-one. This cyclization reaction starts by one of the nitrogen 
atom of nucleophilic centers in 5-thioureido-3-imidazole-4-carboxylic acid derivative 
yields the desired thiazolidin-4-ones28-34. 
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+ R2 NH2R1 CHO
H2O
Et-OH
R2 N
H
R1
HS COOH
S N
O
R1
R2
 
Further, new synthetic route35 for the preparation of 2-isopropyl-3-benzyl-1,3-
thiazolidin-4-ones and 2-phenyl-3-isobutyl-1,3-thiazolidin-4-ones by using 1:1:3 ratio of 
valine, aldehyde and mercaptoacetic acid was reported by Cunico36 et al.,., and suggested 
that the introduction of strong withdrawing group such as NO2 present in benzaldehyde 
favored the synthesis of hetero-cycle (I) in good yields, whereas the methoxy and fluoro 
groups produces the type  (II) thiazolidin-4-ones. In this connection a solvent-free 
synthesis of five-membered heterocyclic thiazolidin-4-ones from phenyl hydrazine and 2,4-
DNP as an amino moiety37. Another method of preparation of 2,3-diaryl-thiazolidin-4-ones 
(III) was established, where saccharomyces cerevisiae enzyme also called as baker’s yeast 
comprising lipase was used as a catalyst in this reaction and accelerated the formation of 
imines as well as cyclo-condensation reaction of aryl aldehydes, amines with thioglycolic 
acid.  
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O
H + HO
O
NH2
H3CO OCH3
+
HS
O
OH N
S
O
OCH3H3CO
N
SH3CO
H3CO
O
+
CHO
R
+
NH2
R1
Saccharomyces cerevisiae
S
N
O
R
R1
R = H, OCH3, Cl, NO2, OH, 
R1 =  H, CH3 and Cl
(II)
(III)
R R
R
(I)
 
Further, the reaction of alkyl or aryl isothiocyanate (IV) with a primary amine 
furnished the corresponding thiourea derivative (V), which directly undergoes cyclization 
reaction by treating with halo acetic acid to yield two isomers of 2-imino-thiazolidin-4-
ones38(VI, VII). In addition, coupling reaction between α-chloro amide derivatives with an 
isothiocyanate in the presence of a mild base such as K2CO3 afforded the iminothiazolidin-
4-one derivatives39 (VIII).  
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R1 NCS
R2 NH2
R1
NH
S
NH R2
N
SN
R2
R1
O
N
S
N
R1
R2
O+
Ar-NH2
Cl Cl
O
Ar-NH
O
Cl
Ar' NCS
K2CO3, CH3CN
SN
O
N Ar'
Ar
(IV)
(V) (VI) (VII)
(VIII)  
N
N
R2
NH
O
O
S
H
N
R1
OCH3
Br
O
OH
EtOH, NaOAc
N
N
R2
N
O
O OCH3
S
N
O
R1
Ar-CHO
N
N
R2
N
O
O OCH3
S
N
O
R1
Ar  
Mechanism of reaction for the preparation of thiazolidinones 
The reaction between substituted thiourea with acid to haloacetic acid produces 2-
imino thiazolidin-4-ones. These reactions occur in polar solvents such as ethyl alcohol 
7 
 
under reflux and in the presence sodium acetate or pyridine40. Substituted thiourea can be 
procured by a reaction with primary amines. Thiourea undergoes asymmetric reactions and 
form two regioisomers, where the regioselectivity is controlled by electronic factors, 
especially the combination of electron-withdrawing substituent (aryl or heteroaryl) with 
nitrogen imino group41.  
R1NH NHR2
S
+ X
OR
O
S N
O
R1
N R2
+ S N
O
R2
N R1
Thiourea
R1 = Aryl or Heteroaryl
R2 = Alkyl
X = Br or Cl
R = H, CH3 or C2H5
Mechanism
R1NH NHR2
S
R1N NHR2
SH X OR
O
S NH
OR
O
N
R1
R2
H
X
S N
O
R1
N R2
OR
H
-HX
S N
O
H
N R2
S N
O
R1
N R2
R1
OR
-ROH
 
Properties of thiazolidin-4-ones 
           The thiazolidin-4- ones are generally solid forms, often melting with decomposition 
but the attachment of alkyl group with the nitrogen minimizes the melting point. The aryl 
or higher alkyl substituent’s of thiazolidin-4-one slightly soluble in water.   
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Chemical properties of thiazolidin-4-ones 
The structure of thiazolidin-4-ones exists in the literatures42. Thiazolidin-4-ones are 
the derivatives of thiazolidine with C=O group at fourth position43. Substitution of various 
groups at 2nd, 4th and 5th position is possible. A different optical isomeric form of 
thiazolidinone is reported in the references44 and number of regioselective isomers has been 
reported45,46. The C=O group of thiazolidin-4-one is highly inert nature. But in few cases 
thiazolidin-4-one on reaction with Lawesson’s reagent gives corresponding thiazolidin-4-
ones47. Tautomer of  2-imino thiazolidine-4-one found to exhibit some chemical interest. 
Several methods are available in order to synthesis a thiazolidin-4-ones in the 
literatures47 which involve conventional, microwave irradiation method and combinatorial 
synthesis. The reaction between NH2 with CS2 in the presence of alkali which then reacts 
with haloalkanoic acid in the presence of  Na2CO3 yields thiazolidin-4-ones. 
Among the various reactions involving the thiazolidin-4-one ring, reactions 
occurring at first position (sulfur) in the oxidation reaction, third position (nitrogen) in N–
alkylation reaction  and mannich reaction,  fourth position (C=O) in thionation reaction via 
Lawesson's reagent49  and fifth position (CH2) in condensation reaction with aldehydes and 
ketones or diazonium salts  is processed. Here by all the above reactions are disussed in 
detail. 
NHS
O
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N–alkylation reaction 
Jelte.N and co-workers50 found that thiazolidin-4-ones substituted in the second 
position with alkyl or alkoxy groups undergo an N-alkylation reaction. In this method, 
equivalent amount of potassium hydroxide was used with thiazolidin-4-ones in anhydrous 
DMF which promotes the formation of amide anion through the abstraction of hydrogen at 
N-3 position and subsequent attack of this anion with 1, 2-dibromo ethane at room 
temperature. The use of potassium hydroxide is essential for the formation of amide anion, 
since thiazolidin-4-one unsubstituted in third position are weak acids. 
S NH
O
R
KOH / DMF
BrCH2CH2 Br
S N
O
R
Br
N-2-bromoethyl-4-thiazolidinone  
Mannich reaction 
Mannich reactions are generally occur between 2-imino thiazolidin-4-ones and NH2 
or NH in presence of formaldehyde or paraformaldehyde in methyl alcohol to produce 2-
imino-3-(substituted amino methyl) thiazolidin-4-one51.  
S NH
O
N R
+
R1NH2
    or
R2NH2
HCHO /CH3OH S N
O
N R
CH2NHR1 or S N
O
N R
CH2NHR2
2-imino-3-aminoalkyl /aryl- 4-thiazolidinone
2-imino-4-thiazolidinone
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Condensation reaction with aldehydes 
The CH2 group at fifth position of thiazolidin-4-one ring due to its acidity it 
undergoes condensation reaction with aldehydes or ketones in knoevenagel reaction52. In 
this reaction, formation of an enolate intermediate is stabilized, which is more dependent 
on the electron attractive effect of the C=O group adjacent to the CH2 group and the 
presence of electron-attractive group at second position of thiazolidin-4-one ring. The 
condensation reaction typically occurs in presence of glacial acetic acid and sodium acetate 
where sodium acetate functions as both alkali and as well as a dehydrating agent in 
piperidine solution or ethanol. 
S NH
O
N R
+ Ar-CHO
CH3CO2Na /
CH3COOH
or
Pyridine / EtOH
   reflux
S NH
O
N R
HC
Ar
2-imino-4-thiazolidinone
2-imino-5-arylidene-4-thiazolidinone  
1.3 CANCER AND ANTI CANCERAGENTS 
Today, the Greek term carcinoma is the medical term for a malignant tumor derived 
from epithelial cells. It is cells us who translated carcinos in to the Latin cancer, also 
meaning crab. Galen used “oncos” to describe all tumors, the root for the modern word 
oncology53. 
Cancer is an important public health on concern and in developed countries it 
represents the second leading cause of death, after cardiovascular disease. The resistance to 
chemotherapeutic anti-tumoragents by cancer cells could be minimized using a 
combination of drugs with different and complementary mechanism of action. Therefore, 
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there is a need to discover and develop useful new lead compounds of simple structure, 
exhibiting optimal invivo anti tumor potency and new mechanism of action. 
Cancer54 is a disease in which a group of cells divides abnormally without any 
control, even destroy other tissues. These cells spread all over the body through the blood 
and lymph, giving rise to satellite lesions elsewhere and then eventually leading to death.   
Cancer is one of the most wide spread and feared diseases in the western world today 
feared largely because it is known to be difficult to cure. The main reason for this difficulty 
is that cancer results from the uncontrolled multiplication of subtly modified normal human 
cells. 
One of the main method so far modern cancer treatments is drug therapy 
(chemotherapy). Cancer is a major disease about one in four people will getting some form 
during their lifetime, and at the present time about one in five of all death are due to cancer. 
Currently the rare three major ways of treating cancer: 
 Radiation therapy 
 Surgery 
 Cytotoxic drugs. 
Cancer arises from the mutation of a normal gene. Mutated genes that cause cancer 
are called oncogenes. A factor which brings about a mutation is called a mutagen. Any 
agent that causes a cancer is called a carcinogen and is described as carcinogenic55. 
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Fig.No.1 Types of cancer scell division  
 
Types of tumor 
1. Benign tumours (do not spread from their site of origin, but can crowd out (squash) 
surrounding cells e.g. brain tumor 
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2. Malignant tumours (can spread from the original site and causes secondary 
tumours. This is called metastasis. They interfere with neighboring cells and can block 
blood vessels, the gut, glands, lungs etc.) 
 
The Cell Cycle 
 
 
 
 
 
 
 
 
 
 
 
Fig.No.2 Phases of Cell cycle 
 The cell cycle consists of four stages G1, S, G2 and M. 
 G1 and G2 are 'gap' phases in which the cell grows and prepares to divide. 
 S is the synthesis phase in which the chromosomes (DNA) are copied (replicated). 
 M is the mitotic phase in which the cell physically divides in to two daughter cells. 
 Most cells are NOT actively dividing. These cells are in a resting state(G). 
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Mitosis (M phase) 
 Mitosis in normal cells produces two cells with identical genetic content.  
Mitosis has four sub-phases.     
 Prophase -Chromosomes condense, then clear membrane breaks down and spindle 
fibres form. 
 Metaphase-The replicated chromosomes line up in the middle of the cell. 
 Anaphase-Chromosomes separate and the cell become elongated with distinct ends 
(poles). 
 Telophase - Nuclear envelopes reform at the two poles and new cell membranes are 
formed to create two independent cells. 
 Cytotoxicity is the cell killing property of a chemical compounds. Cell death can 
occur by either of two distant mechanism, necrosis or apoptosis. 
Necrosis is physical or chemical damage, where apoptosis is the physiological 
process by which unwanted cells are eliminated during development and other normal 
biological processes. 
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Types of cancer 
Lung Cancer Lung 
Breast Cancer Breast 
Cervical Cancer Cervical 
Colon  Cancer Colon 
Leukemia Blood 
Testicular Cancer Testis 
Brain Cancer Brain 
Kidney Cancer Kidney 
Thyroid Cancer Thyroid Gland 
Liver Cancer Liver 
Bone Cancer Bone marrow 
 
                           Table No.1 Types of Cancer 
Causes of cancer 
 DNA Mutation 
1. Radiation – other environmental (tobacco, alcohol, radon, asbestos, 
chemicals etc).  
2. Random somatic mutations 
3. Inherited germ line mutations 
 Genetic predisposition – 
1. Rb, p53, APC, CDKN2A, BRCA1, BRACA 
 Infectious agents 
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1.  Viral 
A. HPV (Human papilloma virus) – cervical cancer 
B. Hepatitis – liver cancer 
2. Bacterial 
A. H. pylori– stomach cancer 
Diagnosis of cancer 
 Biopsy of the tumor 
 Blood tests (which look for chemicals such as tumor makers) 
 Bone marrow biopsy (for lymphoma or leukemia) 
 Chest x-ray 
 Complete blood count 
 CT scan & MRI scan 
Treatment of Cancer Traditional treatment 
1. Surgery: it is the first treatment which is used to removed solid tumors, and for 
early stage cancer and benign tumors. 
2. Radiation: it kills the cancer cells with high energy rays targeted to the tumor. It 
acts by damaging DNA and preventing its replication. 
 Newer treatment 
1. Hormone therapy:  by using Hormones and anti – Hormone. 
2. Chemotherapy: Chemotherapy means treatment with anticancer drugs and they 
are given to destroy or control cancer cells. 
17 
 
 
1.4 CERVICAL CANCER 
The American Cancer Society’s56-60 most recent estimates for cervical cancer in the 
United States are for 2011: 
 About 12,710 new cases of invasive cervical cancer will be diagnosed per year. 
 About 4,290 women will die from cervical cancer per year 
Cervical cancer is one of the most common types of cancer and a majority mortality 
factor of women worldwide. 
The cervix is the lower part of the uterus (womb). The part of the cervix closest to the 
body the uterus is called the endocervix. The part next to the vagina is the exocervix. The 
two main types of cells covering the cervix are squamous cells (on the endocervix). The 
place where these two cell types meet is called the transformation zone. Most cervical 
cancers start in the transformation zone. 
Normally, cervical cells grow in an orderly fashion. However, when controls of that 
grow this lost, cells divide too frequently and too fast. Nearly all cervical cancers arise of 
the inner of the cervix. 
There are several types of cervical cancer: 
           Squamous cell carcinoma61 (SCC) is the most common type of cervical cancer, 
accounting for 85% to 90% of all cases. It develops from the cells that line the inner part of 
the cervix, called the squamous cells. 
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Adenocarcinoma62 develops from the column shaped cells that line the mucous 
producing glands of the cervix. In rare instances, adenocarcinoma accounts for about 10% 
of all cervical cancers. 
Mixed carcinomas (adenosquamouscarcinomas)63 combine features of both 
squamous cell carcinoma and adenocarcinoma. 
Treatment of Cervical Cancer 
 Surgery 
 Pre invasive cervical cancer 
 Cryosurgery 
 Laser surgery 
 Invasive cervical cancer 
1. Simple hysterectomy– removal of the body of the uterus and cervix 2. Radical 
hysterectomy and pelvic lymph node dissection Removal of entire uterus, surrounding 
tissue, upper part of the vagina and lymph nodes from the cervix. 
 Radiation 
 Chemotherapy 
The drugs used to combat cancer belong to one of the two broad categories. The 
first is cytotoxic drugs (cell killing) and the second is cytostatic drugs (cell stabilizing). 
Both the categories lead to a reduction in the size of tumor because cancer cells (for various 
reasons) have such a high mortality rate that simply preventing them from dividing will 
lead to a  reduction in the population. 
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The majority of drugs used for treatment of cancer today are cytotoxic (cell killing) 
drugs that work by interfering in someway with the operation of the cell’s DNA. Cytotoxic 
drugs have the potential to be very harmful to the body unless they are very specific to 
cancer cells something difficult to achieve because the modifications that change a healthy 
cell in to a cancerous one are very subtle. A major challenge is to design new drugs that 
will be more selective for cancer cells, and thus have lesser side effects.The development 
of a new pharmaceutical is a complex process, but can be broken down to three main steps: 
 Discovery of a new potentially use full molecule. 
 Appropriate molecular modification to produce a molecule with the best 
combination of properties. 
 Development of this molecule in to a safe and affordable drug. 
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Fig.No.4 MOA of Cytotoxic drugs 
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2. LITERATURE REVIEW 
Various thiazolidinone derivatives have been developed by structural modifications in 
order to enhance the biological properties such as anticancer, anticonvulsant, CNS 
depressant, analgesic, anti-inflammatory, etc. Here in a detailed literature survey is described 
for thiazolidinone derivatives. 
2.1 ANTICANCER ACTIVITY 
Monforte and co-workers64 in the year 1988 reported the antitumor activity of series 
of 2-alkyl-[2-(1, 3, 4-thiadiazolyl)]-4-thiazolidinones. These compounds were tested against 
the leukemic 388 tumor system. All the compounds were found to exhibited significant 
antitumor activity. 
Duane D Miller and co-workers65 in the year 2004 reported the synthesis, SAR and 
antiproliferative activity of  2-aryl-4-oxo-thiazolidin-3-yl-amides (1) for prostate cancer. 
From this study, three potent compounds have been detected, which were effective in killing 
prostate cancer cells with improved selectivity.   
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(1) 
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Roman Lesyk and co-workers66 in the same year have reported some novel 4-
thiazolidones (2) derivatives and studied their anti-diabetic (insulin-sensitizing), aldose 
reductase, thyromimetic, antimicrobial, antiviral, anti-ischemic, cardiovascular and anticancer 
activity. 
S
N
N
O
R
 
(2) 
In the year 2005, Stefania Carotti and co-workers67 reported in-vitro anti-proliferative 
activity of 4-thiazolidinones against human colon cancer cell lines. The 2-phenyl imino and 
2,4-thiazolidinone (3) derivatives were found to be the most active compounds. 2-Phenyl 
imino derivative inhibits the HT 29 cell line by a high COX-2 expression and 2,4-
thiazolidinones inhibits all cell lines.  
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(3) 
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AmanySayed Maghraby and co-workers68 in the year 2005 reported the synthesis of 
series of new 4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine (4) derivatives incorporated 
thiazolidinone moiety. The synthesized compounds were tested for possible serine prostate 
and cercarialelastase inhibitory effects with a possible prospective to block penetration of 
schistosomamansonicercariae in to the skin. 
N
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(4) 
Benaka Prasad and co-workers69 in the year 2008 synthesized a series of novel 5-(4-
methyl benzylidene)-thiazolidine-2,4-dione (5) derivatives with different substituted aromatic 
sulfonyl chlorides and alkyl halides. The synthesized compounds were evaluated for their cell 
antiproliferative activity by MTT assay. The nitro group in the 4th position on aryl ring plays 
a dominant role and was responsible for the antiproliferative activity.  
N
S O
O R
H3C
 
(5) 
Shuhong Wu and co-workers70 in the year 2008 reported the synthesis of 
pharmacophore of thiazolidinone derivatives. The synthesized compounds were evaluated for 
their structure activity relationship, cytoselective toxicity and anti-cancer activity.   
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In the year 2009 Rosanna Maccari and co-workers71 synthesized 4-(5-arylidene-4-
oxo-2-phenylimino thiazolidin-3yl)-methyl benzoic acids (6) and screened their inhibitory 
activity against human PTP1b and LMW-PTP enzymes. Among the evaluated compounds, 
the 5-arylidene substituted moiety proved the potency. 
N
S
N
Ar
COOH
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(6) 
 In the same year, Zimenkovsky and co-workers72 have synthesized a novel nonfused 
bicyclic thiazolidinones. These compounds were screened for their anticancer activity. 
Among the tested compounds, the compound 2-(4-oxo-3-furyl methyl-4-oxothiazolidin-5-yl-
N-4-chlorophenyl) acetamide was found to be more potent anticancer agent than the standard 
compound. 
HavrylyukDmytro and co-workers73 in the year 2010 reported the synthesis and 
anticancer activity evaluation of 4-thiazolidinones (7) containing benzothiazole moiety. 
These compounds were screened for in-vitro anticancer activity. The activity data exhibits 
that all compounds were found to show potent anticancer activity. 
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(7) 
Kaminskyy DV and co-workers74 in the year 2010 described the structure–anticancer 
activity relationships among 4-thiazolidinone-3-carboxylic acids derivatives. 
In the year 2010, IvannaSubtelna and co-workers75 synthesized the 5-arylidene-2-
amino-4-thiazolones (8) and evaluated their anticancer activity. The synthesized compounds 
were found to possess a good anticancer activity. Among the tested one, the compounds 5-(4-
chlorobenzylidene)-2-(4- hydroxyl phenyl amino) thiazol-4-one and 5-(2-chloro-3-(4-
nitrophenyl)-2-propenylidene)-2-(3-hydroxyphenylamino) thiazol-4-one were found to 
possess high effect on all leukemia cell lines.  
N
N
H
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Ar
O
R3
 
(8) 
In the year 2011 Maity TK and co-workers76 reported the synthesis, characterization 
and antiproliferative activity of 2-(substituted phenyl)-5-methyl-3-pyridin-4yl-1,3-
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thiazolidinones. These compounds were evaluated for in-vitro cytotoxicity against lymphoma 
cancer cell lines at varies concentrations. Among the tested compounds, two compounds 
showed highest cytotoxic activity against L929 cell lines. 
A series of regioselective 3-thiazolidine acetic acid derivatives were synthesized by 
Zhengming Li and co-workers77 in the year 2011. These compounds were evaluated for anti-
tumor activity. The results of bioactivity data showed that modification at the C-H of amino 
acid, N-(per-o-acetyl glycosyl amino) thioxo methyl) ethyl ester results in great influence on 
anti-tumor activity. 
 Ping Gong and co-workers78 in the year 2012 reported the design and synthesis of 2-
iminothiazolidin-4-one moiety-containing compounds as potent antiproliferative agents. The 
Pharmacological data indicated that most of the compounds possessed moderate activity, 
some showed remarkable activity.  
2.2 ANTIDIABETIC ACTIVITY 
Pattan and co-workers79 in the year 2005 reported the synthesis and anti-diabetic 
activity of 2-amino [5 (- 4 - sulfonylbenzylidine) - 2,4-thiazolidindione] -7- chloro – 6 - 
flurobenzothiazole. The synthesized compounds were found to possess potent anti-diabetic 
activity. 
  In the year 2009, Firake BM and co-workers80 reported the synthesis of series of N-
ary/alkyl substituted pyridine thiazolidinones(9). These compounds were screened for their 
antidiabetic acitivity on wistar-strain rats and acute toxicity. All the tested compounds were 
found to possess good antidiabetic activity. 
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(9) 
Suroor Ahmad Khan and co-workers81 in the same year have prepared a series of 2-
substituted phenyl-3-(1-naphthyl)-1,3-thiazolyl-amino-4-oxo thiazolidin acetic acid 
derivatives and evaluated their anti-hyperglycemic activity. The bioactivity results revealed 
that all compounds possess more potent antihyperglycemic activity. 
In the year 2010, VipanKamboj and co-workers82 synthesized a series of 3-(4-
alkyl/arylsubstituted)-4-oxo-1,3-thiazolidin-2-ylidene acetohydrazide(10). All the compounds 
were screened for their antidiabetic activity. Among the tested compounds, the compound 3-
phenyl substituted-4–oxo-1,3-thiazolidin-2-ylidene acetohydrazide possess high activity with 
reduced toxicity.  
S
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N  
(10) 
Synthesis of 5-substituted-1,3-thiazolidin-4-ones (11) as anti-hyperglycemic activity 
was reported by BirendraSrivastava and co-workers83 in the year 2010. These compounds 
were found to possess good anti-hyperglycemic activity.  
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DeepthiKini and co-workers84 in the year 2011 reported the synthesis of new series of 
3-(5-methyl-2-aryl-3-thiazolylamino)-4- thiazolidinone coumarin derivatives. The prepared 
compounds have been evaluated for their oral hypoglycemic activity. Among the tested 
compounds, the compound 3-(5–methyl–3-(4–nitrophenyl)–3-thiazolylamino-4-
thiazolidinone coumarin exhibited high profile of activity when compared to standard. 
2.3 ANTI-VIRAL ACTIVITY 
FaridBadria and co-workers85 in the year 2003 synthesized a new thiazolidinone and 
oxadiazoline coumarin(12) derivatives and investigated their antiviral activity, cytotoxicity 
and SAR studies. All compounds were found to exhibits high antiviral profiles. 
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(12) 
29 
 
Synthesis of benzimidazole and thiazolidinone derivative (13) as HIV-1 RT inhibitors 
by microwave irradiation technique was reported by Anna Maria Monforte et al.,86 in the year 
2004. Among the evaluated compounds the compound 2-(2,6-difluorophenyl)-3-(3-
methoxyphenyl)-1,3-thiazolidin-4-one emerged as potent HIV-1 with marked RT inhibitory 
affects. 
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(13) 
Zappala and co-workers87 in the year 2004 synthesized 1,3-thiazolidinones with 
dihalogen and pyrimidine substitution. The prepared compounds were screened for their 
HIV-1 reverse transcriptase enzyme inhibition studies. From the activity data it was found 
that all the compounds were found to possess good HIV-1 activity.      
In the year 2005, Dharmarajan Sriram and co-workers88 reported the synthesis and 
anti-YFV activity of 2, 3-diaryl-1,3-thiazolidin-4-ones (14) by microwave-assisted reaction. 
The synthesized compounds were evaluated for their inhibitory effects on the replication of 
YFV in green monkey kidney (Vero) cells (ATCC CCL81), by means of a cytopathic effect 
reduction assay. 
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(14) 
Ravindra K Rawal and coworker89 in the year 2007 reported molecular docking 
studies of 4-thiazolidinones as HIV-1 RT inhibitors. The docking studies provided an insight 
into the pharmacophoric structural requirements for the HIV-1 RT inhibitory activity of this 
class of molecules. 
In the year 2011, Ravichandran Veerasamy and co-workers90 has reported the design, 
synthesis and biological evaluation of thiazolidinone derivatives as potent anti-viral agents. 
All the compounds possessed high degree of antiviral potential. 
2.4 ANTIMYCOBACTERIAL AND ANTIFUNGAL ACTIVITY 
Evelin Boshra and co-workers91 in the year 1989 reported some new heterocyclic 
thiazolidines(15) with acaricidal, insecticidal and bactericidal activity. The reported 
compounds were found to possess a good bactericidal and inseticidal activities. 
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(15) 
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In the year 1990, HamedEad and co-workers92 reported a cycloaddition reaction of 
series of 5-(2-thienyl) methylene (16) derivatives of thiazolidinone-4-thiones. The 
synthesized compounds were screened for antimicrobial activities. The results of biological 
activity expressed that all compounds were more potent in nature. 
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(16) 
 Preparation of quinoxaline derivatives containing thiazolidinone (17) residue as a 
potent antibacteial and antifungal agent was reported by Afaf K Ansary and co-workers93 in 
the year 1995. All the compounds were found to exhibit significant antimicrobial activity. 
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(17) 
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Sayed R and co-workers94 in the year 1999 synthesized a novel compound 2-[2-
carboxy methylthio-2-(4-chlorophenyl) ethyl]-2-(4-chlorophenyl)-4-thiazolidinone (18) and 
studied its biological potency.  
Cl
S NH
O
CH2 CH
HS CH2 COOH
Cl
 
(18) 
 
2.5. ANTICONVULSANT ACTIVITY 
In the year 1996, Ulusoy and co-workers95 have reported the synthesis, 
characterization and anticonvulsant evaluation of bis-thiazolidin-4-one (19). The results of 
biological activity indicate that substitution of phenyl group at 3rd position and alkyl group at 
4th position results in potent activity. 
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(19) 
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Aysel and co-workers96 in 2005 have synthesized and isolated a new series of 2,3-
regioisomeric substituted-4-thiazolidinones (20). These compounds were screened for their 
anticonvulsant activity. The anticonvulsant data showed that substitution at 3rd position favors 
pronounced activity. These compounds were found to possess good anticonvulsant activity. 
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(20) 
Kailash and co-workers97 in the year 2007 reported the new series of triazole 
substituted thiazolidinone derivatives (21). These compounds were evaluated for their 
neurotoxicity and anticonvulsant activity in two animal models of seizures. The results of 
screening data shown that, three compounds exhibited excellent anticonvulsant activity. 
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     (21) 
Huger and coworkes98 in the year 2010 have synthesized a group of thiazolidinones 
containing 2-mercapto benzimidazole moiety (22) and screened them for in-vivo 
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anticonvulsant activity by maximal electroshock (MES) model. The activity data reveals that 
all the synthesized compounds were found to possess potent anticonvulsant activity. 
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(22) 
In the same year synthesis and anticonvulsant activity of novel substituted 
thiadiazolylazetidinonyl derivatives (23) were reported by Saxena and co-workers99. The 
activity data concludes that among the synthesized compounds, some of the title compounds 
exhibited promising anticonvulsant activity. 
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(23) 
Rangappa and co-workers100 in the same year reported synthesis of group of 
thiazolidin-4-ones and 1,3,4-oxadiazoles containing mercapto benzimidazoles(24). The 
synthesized compounds were screened for in-vivo anticonvulsant activity by MES model and 
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antidiabetic activity. All the compounds were exhibited potent anticonvulsant and 
antidiabetic activities. 
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(24) 
In the year 2011, Ganesh Akula and co-workers101 prepared a series of benzimidazolyl 
amino thiazolidin-4-ones (25). These   compounds were screened for anticonvulsant activity 
by the MES induced seizure model. All the compounds were significantly showed their 
anticonvulsant activity similar to that of standard. 
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(25) 
Tejprakash and co-workers102 in the same year have synthesized and characterized a 
series of substituted 5-ethylidene-2-pheny limino-4-thiazolidinones (26). These compounds 
were screened for their anticonvulsant activity. From the results they concluded that 
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substitution in 5th position with electrophilic groups such as nitro group shows good 
anticonvulsant activity than the nucloephilic groups such as methoxy and methyl group. 
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26) 
Nikalje and co-workers103in the same year reported a series of 2-dioxoisoindolin-N-4-
oxo substituted thiazolidinylacetamide derivatives (27). All the compounds were evaluated 
for anticonvulsant and CNS depressant activity in mice by MES and pentylenetetrazole 
induced seizure model and also screened their neurotoxicity. The results reveals that all the 
compounds were showed protection against MES test to inhibit seizure. 
 
 
 
 
(27) 
In the year 2012, Indulatha et al. 104 have reported the synthesis of novel N-4-oxo-2-
aryl and heteroaryl substituted thiazolidin-3-yl-3-carboxamido-2H-chromen-2-ones (28) as 
potent anticonvulsant agents. The activity results indicated that all the compounds exhibited 
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63 percent protection which is an indicative of having ability to prevent seizure spread at the 
dose level of 100 mg/kg when compared to the standard drug. 
 
 
(28) 
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CHAPTER-3 
RESEARCH ENVISAGED 
3.1 Objective of the Present Work 
          Thiazolidinones possess a wide spectrum of biological and pharmacological activity 
due to the presence of nitrogen and sulfur which is considered to be responsible for the 
structural features to impart their activities. 
          Despite the optimal use of available anticancer drugs (ACDs), many patients fail to 
experience therapeutic efficacy and others do so only at the expense of significant toxic side 
effects. The limitations with the conventional ACDs highlighted the need for developing 
newer anti-cancer agents with new, less toxic and more effective drugs are required. 
Thiazolidinones are five membered ring system containing sulphur and nitrogen atom, 
received a much attention of medicinal chemists due to their potential biological activities. 
Various substituents’ at C-2 and C-3 of thiazolidinone results in potent anticancer activity. 
Prompted by these reports, we aimed to prepare the following series of 2, 3-disubstituted-
Thiazolidinone derivatives as potent anticancer agents.  
Hence the specific aims & objectives of the present study are, 
 To synthesize a series of novel 2, 3-disubstituted thiazolidinones. 
 To characterize the synthesized compounds by IR, NMR, Mass   spectra and 
elemental analysis. 
 To evaluate the test compounds for anti-cancer activity by using human cervical 
cancer cell line (HeLa) by MTT assay method.  
The title compounds are planned to synthesize by using the following synthetic routes 
mentioned in the following Schemes.   
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Scheme 
Synthesis of 2-(3- (4- (4-aminophenylsulfonyl) phenyl)-2-(2-phenylsubstituted)-4 
oxothiazolidin-5-yl) acetic acid (TD1-7). 
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CHAPTER–4 
4.1 EXPERIMENTAL WORK 
4.1.1  MATERIALS AND METHODS 
Melting points (mp) were taken in open capillaries on Thomas Hoover melting point 
apparatus and are uncorrected. The IR spectra were recorded in film or in potassium bromide 
disks on a Perkin-Elmer 398 spectrometer. The 1H spectra were recorded on a DPX-500 MHz 
Bruker FT-NMR spectrometer. The chemical shifts were reported as parts per million (δ ppm) 
tetramethylsilane (TMS) as an internal standard. Mass spectra were obtained on a JEOL-SX-102 
instrument using fast atom bombardment (FAB positive). Elemental analysis was performed on 
a Perkin-Elmer 2400 C, H, N analyzer and values were within the acceptable limits of the 
calculated values. The progress of the reaction was monitored on readymade silica gel plates 
(Merck) using chloroform-methanol (9:1) as a solvent system. Iodine was used as a developing 
agent. Spectral data (IR, NMR and mass spectra) confirmed the structures of the synthesized 
compounds and the purity of these compounds was ascertained by micro analysis. Elemental 
(C,H,N) analysis indicated that the calculated and observed values were within the acceptable 
limits (± 0.4%). All chemicals and reagents were obtained from Aldrich (USA), Lancaster (UK) 
or Spectrochem Pvt.Ltd (India) and were used without further purification. 
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4.1.1.1 General procedure for synthesis of 2-(5-amino-1,3,4-thiadiazol-2-yl)phenol 
(TD1-7) 
   4-(4-aminophenylsulfonyl) benzenamine (2.48gm) (0.01mol) and substituted 
benzaldehydes (1.47gm) (0.01mol) were dissolved in alcohol (30ml) in a 250ml round bottom 
flask. To this concentrated sulphuric acid (0.5ml) and dry dioxane (12ml) was added with 
constant stirring. To this mixture, 2-mercapto succinic acid (1.5 gm) (0.01mol) in 12ml of dry 
dioxane was added slowly and refluxed for 3 hr at 800C with occasional shaking. The reaction 
completion was monitored by thin layer chromatography. The solid mass separated was poured 
in to ice cold water and filtered. The solid was neutralized with one percent sodium carbonate 
solution, filtered and dried. The residue was recrystallized from methanol.  
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4.1.1.2 Synthesis of 3-(4-(4-aminophenylsulfonyl) phenyl)-2-(2-nitrophenyl)-4-
oxothiazolidin-5-yl) acetic acid (TD1) 
Yield                             : 2.86 g; 81.0 %  
Melting Point                : 216-218 °C 
Rf Value                                  : 0.85 (benzene : ethylacetate(8:2)) 
Molecular Formula       : C23H19N3O7S2   
Molecular Weight         : 513(M+) 
IR (KBr) cm-1                        : 3520 (OH), 3290 (NH2), 3045 (Ar-CH),  
  NO2 (1534),1620 (C=N Str), SO2(688) 675 (C-S-C).                                          
1H NMR (CDCl3) δ ppm :1H NMR (CDCl3) δ (ppm): 2.82-3.07 (d, 1H, CH2), 3.80   
(d,1H,CH),4.01(s,2H, NH2), 6.63 (d, J = 8.0 Hz, 2H, Ar-H), 7.27-
7.95 (m, J =8.0Hz, 8H, Ar-H).  
Elemental Analysis  
Calculated                    : C, 53.79; H, 3.73; N, 8.18.  
Found                           : C, 53.76; H, 3.71; N, 8.17.  
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4.1.1.3 Synthesis of 3-(4-(4-aminophenylsulfonyl)phenyl)-2-(4-(dimethylamino)phenyl)-4-
oxothiazolidin-5-yl)acetic acid (TD 2). 
Yield                             : 2.90 g; 89.0 %  
Melting Point                : 245-247 °C 
Rf Value                        : 0.72 (benzene:ethylacetate(8:2)) 
Molecular Formula       : C25H25N3O5S2 
Molecular Weight         : 511(M+) 
IR (KBr) cm-1                      : 3516 (OH), 3290 (NH2), 3045 (Ar-CH), 
1710 (C=O),1622 (C=NStr), 676 (C-S-C),1289 
(N(CH3)2),(1191)SO2. 
1H NMR (CDCl3) δ ppm :1H NMR (CDCl3) δ (ppm): 2.82-3.07 (d, 2H, CH2), 2.85   
                                     (d, 6H,(CH3)2,3.80 (d,1H,CH),4.01(s,2H, NH2), 6.63 (d, J   
                                      = 8.0 Hz, 2H, Ar-  H), 7.27 (d, J =7.5Hz, 2H, Ar-H), 7.65   
                                     (d, J = 7.0 Hz, 2H, Ar-H), 7.95 (d, J = 7.0 Hz, 2H, Ar-H).                                     
Elemental Analysis 
Calculated                    : C, 58.69; H, 4.93; N, 8.21. 
Found                           : C, 58.67; H, 4.91; N, 8.20. 
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4.1.1.4 Synthesis of 3-(4-(4-aminophenylsulfonyl)phenyl)-2-(4-methoxyphenyl)-4-
oxothiazolidin-5-yl) acetic acid (TD 3). 
Yield                             : 2.68 g; 79.0 %  
Melting Point               : 227-229 °C 
Rf Value                       : 0.78 (benzene:ethylacetate(8:2)) 
Molecular Formula       : C24H22N2O6S2 
Molecular Weight          : 498(M+) 
IR (KBr) cm-1                     : 3516 (OH), 3290 (NH2), 3045 (Ar-CH), 1622 (C=N  
          Str), 676 (C-S-C), 2816 (OCH3), 
1H NMR (CDCl3) δ ppm :1H NMR (CDCl3) δ (ppm): 2.82-3.07 (d, 2H, CH2),  
3.73(s, 3H, CH3),3.80 (d,1H,CH),4.01(s,2H, NH2), 6.63 (d, J = 
8.0 Hz, 2H, Ar-  H), 7.27 (d, J =7.5Hz, 2H, Ar-H), 7.65 (d, J = 
7.0 Hz, 2H, Ar-H), 7.95 (d, J = 7.0 Hz, 2H, Ar-H).                                   
Elemental Analysis 
Calculated                     : C, 57.82; H, 4.45; N, 5.62. 
Found             : C, 57.80; H, 4.45; N, 5.61 
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4.1.1.5 Synthesis of (3-(4-(4-aminophenylsulfonyl) phenyl)-2-(4-hydroxyphenyl)-4-
oxothiazolidin-5-yl) acetic acid (TD 4). 
Yield                             : 2.47 g; 81.0 %  
Melting Point                : 197-199 °C 
Rf Value                       : 0.76 (benzene: ethyl acetate(8:2)) 
Molecular Formula       : C23H20N2O6S2  
Molecular Weight         : 484(M+) 
IR (KBr) cm-1                        : 3522 (OH, broad), 3287 (NH2), 3045 (Ar-CH), 1620 
            (C=N Str), 675 (C-S-C). 
1H NMR (CDCl3) δ ppm :1H NMR (CDCl3) δ (ppm): 2.82-3.07 (d, 2H, CH2), 3.80  
(d,1H,CH),4.01(s,2H, NH2), 6.63 (d, J = 8.0 Hz, 2H, Ar-  H), 7.27 
(d, J =7.5Hz, 2H, Ar-H), 7.65 (d, J = 7.0 Hz, 2H, Ar-H), 7.95 (d, 
J = 7.0 Hz, 2H, Ar-H), 11.0(s, 1H, OH).                         
Elemental Analysis 
Calculated                     : C, 57.01; H, 4.16; N, 5.78 
Found                           : C, 57.00; H, 4.15; N, 5.77 
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4.1.1.6. Synthesis of (3-(4-(4-aminophenylsulfonyl)phenyl)-4-oxo-2-styrylthiazolidin-5-yl) 
acetic acid  (TD 5). 
Yield                             : 2.12 g; 64.0 %  
Melting Point                : 245-247 °C 
Rf Value                       : 0.64 (benzene: ethyl acetate(8:2)) 
Molecular Formula       : C25H22N2O5S2 
Molecular Weight          : 494(M+) 
IR (KBr) cm-1                        : 3508 (OH), 3286 (NH2), 3048 (Ar-CH), 1618 (C=N  
           Str), 674 (C-S-C),(1510 ) CH=CH. 
1H NMR (CDCl3) δ ppm :1H NMR (CDCl3) δ (ppm): 2.82-3.07 (d, 2H, CH2), 3.80 
(d,1H,CH),4.01(s,2H, NH2), 6.63 (d, J = 8.0 Hz, 2H, Ar-  H), 7.21 
(d, J =7.5Hz, 2H, Ar-H), 7.27 (d, J =7.5Hz, 2H, Ar-H), 7.30 (d, J 
=7.5Hz, 2H, Ar-H), 7.65 (d, J = 7.0 Hz, 2H, Ar-H), 7.95 (d, J = 
7.0 Hz, 2H, Ar-H), 10.2(s, 1H, OH).                               
Elemental Analysis 
Calculated                    : C, 60.71; H, 4.48; N, 5.66  
Found                      : C, 60.69; H, 4.47; N, 5.65 
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4.1.1.7 Synthesis of (3-(4-(4-aminophenylsulfonyl)phenyl)-2-(4-aminophenyl)-4-
oxothiazolidin-5-yl)acetic acid (TD 6). 
Yield                             : 2.32 g; 76.0 %  
Melting Point                : 187-189 °C 
Rf Value                       : 0.72 (benzene: ethyl acetate(8:2)) 
Molecular Formula       : C23H21N3O5S2  
Molecular Weight          : 483(M+) 
IR (KBr) cm-1                        : 3310 (NH2, broad ), 3042 (Ar-CH), 1619 (C=N  
              Str), 672 (C-S-C). 
1H NMR (CDCl3) δ ppm :1H NMR (CDCl3) δ (ppm): 2.82-3.07 (d, 2H, CH2), 3.80 
(d,1H,CH),4.08(d ,2H, NH2), 6.34 (2, J = 8.0 Hz, 2H, Ar-  H), 
6.63 (d, J = 8.0 Hz, 2H, Ar-  H), 7.27 (d, J =7.5Hz, 2H, Ar-H), 
77.65 (d, J = 7.0 Hz, 2H, Ar-H), 7.95 (d, J = 7.0 Hz, 2H, Ar-H), 
10.3(s, 1H, OH).                               
Elemental Analysis 
Calculated                   : C, 57.13; H, 4.38; N, 8.69  
Found                          : C, 57.11; H, 4.37; N, 8.68 
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4.1.1.8 Synthesis of (3-(4-(4-aminophenylsulfonyl)phenyl)-2-(4-chlorophenyl)-4-
oxothiazolidin-5-yl) acetic acid (TD 7). 
Yield                            : 2.15 g; 74.0 %  
Melting Point                : 177-179 °C 
Rf Value                       : 0.70 (benzene: ethyl acetate (8:2)) 
Molecular Formula       : C23H19ClN2O5S2  
Molecular Weight          : 502(M+), 504(M+) 
IR (KBr) cm-1                         :3298 (NH2), 3040 (Ar-CH), 1617 (C=N  
          Str), 670 (C-S-C),688(C-Cl). 
1H NMR (CDCl3) δ ppm :1H NMR (CDCl3) δ (ppm): 2.82-3.07 (d, 2H, CH2), 3.80 
(d,1H,CH),4.01(s,2H, NH2), 6.63 (d, J = 8.0 Hz, 2H, Ar-  H), 7.00 
(d, J =7.5Hz, 2H, Ar-H), 7.15 (d, J =7.5Hz, 2H, Ar-H), 7.27 (d, J 
=7.5Hz, 2H, Ar-H), 7.65 (d, J = 7.0 Hz, 2H, Ar-H), 7.95 (d, J = 
7.0 Hz, 2H, Ar-H), 10.2(s, 1H, OH).                                
Elemental Analysis 
Calculated                    : C, 54.92; H, 3.81; Cl, 7.05; N, 5.57 . 
Found                         : C, 54.90; H, 3.80; Cl, 7.04; N, 5.56 .  
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4.2 CHROMATOGRAPHY STUDIES OF SYNTHESIZED COMPOUNDS 
4.2.1 THIN LAYER CHROMATOGRAPHY 
             Thin Layer Chromatography or TLC is a solid-liquid form of chromatography here the 
stationary phase is a polar absorbent and the mobile phase can be a single solvent or 
Combination of solvents. TLC is in expensive technique and quick that can be used for 
determine the number of components in a mixture, verify a substance’s identity, monitor the 
process of a reaction, determine appropriate condition for column chromatography, analyze the 
fractions obtained from column chromatography. 
4.2.1.1 MATERIALS AND METHODS 
1. Preparation of plates 
Silicagel G was mixed in a glass mortar to smooth consistency with the requisite amount of 
water and slurry was quickly transferred to hespreader. The mixtures have been spread over the 
plates in thickness of 0.2mm and allow setting in to a suitable holder and after 30 minutes; 
plates were dried at 120oC, for further activation of the absorbent. 
2. Sample application 
        About 2 mm of absorbent from the edge of plate was removed to gives sharply defined 
edges. 2-5µl volumes of synthesized compounds were spotted with the help of capillary tubes, 
just above 1cm of the bottom of coated plates. 
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3. Development chamber 
           The chromatographic chamber was lined with filter paper dipping in to mobile phase so 
as to maintain the atmospheric saturation with solvent vapors in the chamber. The solvent front 
was allowed to rise to distance of about 12cm from the baseline on the plate was removed from 
the tank and allowed to dry in the air. 
4. Solvent system 
The choice of best developing solvent is one of the most important decisions in practical 
TLC by review of literature survey on by knowing nature of compounds, this solvent system 
used is benzene: ethyl acetate (8:2). 
5. Detection of components 
The spots were visualized under Iodine chamber. 
4.2.2 COLUMN CHROMATOGRAPHY 
Purification of synthesized derivatives was done by column chromatography. 
Materials  
1.   Glass column of size 45cm x 3cm. 
2.   Silicagel for column chromatography 60-120 mesh size. 
3.   Eluting solvent system benzene :ethylacetate (8:2). 
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Preparation of column 
         The silica gel 60-120 mesh size was made in to slurry with the above solvent system. The 
bottom of the column was plugged with little glass wool. Then the slurry was poured in to the 
column, which is filled with solvent after two third of the column areas were filled with slurry. It 
was set aside for 30 minutes and eluting solvent was passed through column for several time 
ensure good packing of the column. After the adsorbents are settled, a filter paper was kept to 
prevent disturbance of the two player of the adsorbent as fresh mobile phase to be added to 
column for the process of elution. The fractions were collected for every 5m land analyzed for 
the presence of different of similar compound by running TLC and then allow evaporating to get 
the residue. 
 4.3. PHARMACOLOGICAL SCREENING 
4.3.1. IN-VITRO ANTI-CANCER ACTIVITY 
Tissue culture has been used  to screen may anti-cancer drugs since  there  is clear 
correlation  between  the in  vitro and in  vivo activities  of  potential  chemotherapeutic agents.  
There  is  scientific  justification  for  cytotoxicity  testing  in  tissue,  since  animal models are  
in many ways  in adequate for predicting  the effects of chemicals on humans since there are 
many metabolic differences between species61-63. 
Cytotoxicity studies involve the analysis of morphological damage or inhibition of zone 
of outgrowth induced by the chemicals tested. 
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ASSAY FOR PROLIFERATION STUDIES 
IN VITRO ANTI CANCER ACTIVITY 
          The human cervical cancer cell line (HeLa) was obtained from national center for 
cell science (NCCS)  pune. The HeLa  cells were grown  in Eagles Minimum Essential Medium  
containing  10%  fetal  bovine  serum  (FBS)  and maintained  at  37°C,  5% CO2, 95% air and 
100%  relative humidity. Maintenance cultures were passaged weekly, and the culture medium 
was changed twice a week. 
 Toxicity  of  test  compound  in  cells  was  determined  by  MTT  assay  based  on 
mitochondrial  reduction  of  yellow  MTT tetrazolium  dye  to  a  highly  colored  blue 
formazan product40. 
Assay for Proliferation Studies - MTT Assay 
Principle  
MTT [(3-(4,5-dimethyl thiazol-2yl)-2,5diphenyl tetrazolium bromide] measures the 
metabolic activity of the viable cells. The assay can be performed entirely in a microtiterplate 
(MTP). It is suitable for measuring cell proliferation, Cell viability or Cytotoxicity. The reaction 
between MTT and mitochondrial dehydrogenase produces water-insoluble formazan salt. This 
method involves culturing the cells in a 96 well microtiterplate and then incubating with MTT 
solution for approximately 2 hours. During incubation period, viable cells convert MTT to a 
water insoluble formazan dye. The formazan dye in the MTP is solubilized and quantified with 
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an ELISA plate reader. The absorbance directly correlates with the cell number. This is 
applicable for adherent cells cultured in MTP. 
Materials for MTT assay 
 The human cervical cancer cell line (HeLa) Eagles Minimum Essential Medium 
containing 10% fetal bovine serum (FBS). 
 Phosphate buffered saline (PBS) 
 Dimethyl sulphoxide (DMSO) 
 MTT [(3-(4,5-dimethylthiazol-2yl)-2,5 di phenyl tetrazolium bromide]CO2 incubator 
(WTC Binder, Germany) 
 Laminar air flow cabin (Klenzaids, Chennai, India). 
 Refrigerated centrifuge ( Biofuge fresco, Heraeus, Germany). 
 ELISA-reader ( For MTP ) Anthos 2010, Germany). 
 Deep freezer (Polar Angelantioni Industries, Italy). 
 Ultrazonic bath ( Transonic [ 460/H ], by Elma, Germany]. 
 Vaccum pump ( Zenith [model: PDF-2-2.5], Mumbai, India). 
 Pipettes (Eppendoff, Hamburg, Germany). 
 Culture plates 
 Centrifuge tubes 
 Aerosol resistant tips 
 Flat-bottomed 96-MTP 
 Tissue culture grade 
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Cell treatment procedure 
      Cell treatment procedure the monolayer  cells were detached with  trypsin-ethylene 
diamine tetraacetic  acid (EDTA)  to  make  single  cell  suspensions  and  viable  cells  were  
counted  using  a hemocytometer  and  diluted with medium with  5%  FBS  to  give  final  
density  of  1x105 cells/ml.  one  hundred microlitres  per well  of  cell  suspension were  seeded  
into  96-well plates at plating density of 10,000 cells/well and incubated to allow for cell 
attachment at 370C, 5% CO2, 95%  air  and 100%  relative humidity.  
After 24 h the cells were treated with serial concentrations of  the extracts and  fractions. 
They were  initially dissolved  in neat  dimethylsulfoxide  (DMSO)  and  further  diluted  in  
serum  free medium  to  produce five concentrations. One hundred microlitres per well of each 
concentration was added to plates to obtain final concentrations of 100, 10, 1.0 and 0.1 µM. The 
final volume in each well was  200  µl  and  the  plates were  incubated at  370 C, 5% CO2,  95%  
air  and  100% relative  humidity for  48h.  The medium containing without samples were  
served  as control. Triplicate was maintained for all concentrations.  
Procedure 
In-vitro anticancer screening 
The human cervical cancer cell line (HeLa) was obtained from National Centre for Cell 
Science (NCCS), Pune. The cells were grown in Eagles Minimum Essential Medium containing 
10%  fetal bovine serum (FBS)63. 
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For screening experiment, the cells were seeded into 96-well plates in 100µl of medium 
containing 5 %  FBS, at plating density of 10,000 cells/well and incubated at 37 0C, 5 % CO2, 
95 % air and 100 % relative humidity for 24 hours prior to addition of samples. The samples 
were solubilized in Dimethylsulfoxide and diluted in serum free medium. After 24 hours, 100 µl 
of the medium containing the samples at various concentration ( eg; 0.063, 0.125, 0.25, 0.5, 1.0 
mM etc… ) was added and incubated at 370C, 5% CO2, 95% air and 100% relative humidity for 
48 hours. Triplicate was maintained and the medium containing without samples were served as 
control41. 
After 48 hours, 15µl of MTT (5mg/ml) in phosphate buffered saline (PBS) was added to 
each well and incubated at 37 0C for 4 hours. The medium with MTT was then flicked off and 
the formed formazan crystals were solubilized in 100µl of DMSO and then measured the 
absorbance at 570 nm using micro plate reader. The % cell inhibition was determined using the 
following formula % cell Inhibition= 100 – {(sample) / Abs (control)}× 100. 
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Invitro Cytotoxicity Studies on Human Cervical Cancer Cell line (HeLa) 
 
 
PERCENTAGE OF CELLINHIBITION 
 
Table No.2. 
  
Compounds Concentration    % Cell 
Inhibition 
Compounds Concentration % Cell 
Inhibition 
TD1 
0.1 µM 1.5342 
TD5 
0.1 µM 1.4112 
1 µM 12.9079 1 µM 13.7176 
10 µM 30.9861 10 µM 23.8976 
100 µM 62.8578 100 µM 51.3006 
TD2  
0.1µM 1.0424  
TD6 
0.1µM 1.1895 
1µM 10.4447 1 µM 12.2646 
10 µM 22.9848 10 µM 23.6772 
100 µM 52.8995 100 µM 55.0587 
TD3 
0.1µM 1.4579  
TD7 
0.1 µM 1.3342 
1µM 11.0145 1 µM 14.6079 
10 µM 28.2358 10 µM 33.8761 
100 µM 70.1268 100 µM 74.8578 
TD4 
0.1 µM 1.4824 
1 µM 11.6447 
10 µM 29.9848 
100 µM 72.8995 
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  Nonlinear  regression  graph  was  plotted  between  %  Cell  inhibition  and  Log10 
concentration and IC50 was determined using GraphPad Prism software.   
Statistical Analysis 
All values are expressed as mean ± SEM. Data were analyzed by non-parametric 
ANOVA followed by Dunnett’s multiple comparison tests, and other data was evaluated using 
Graph Pad PRISM software. A p-value < 0.05 was considered significantly different. 
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    Fig.No.5 Percentage Cell Inhibition on Human Cervical Cancer Cell Line (HeLa) 
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           Table No.3: IC50 Values of Synthesized Compounds (TD1–TD7) 
 
 
 
COMPOUND  CODE 
 
 
IC50 (MICRO MOLAR) 
 
TD1 
 
45.70 µM 
TD2 
 
66.23 µM 
TD3 
 
75.26 µM 
TD4 
 
92.36 µM 
TD5 
 
68.25 µM 
TD6 
 
48.60 µM 
 
TD7 
   
 
           >100 µM 
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Table No.4 TD1 
 
 
Concentration (µM) 
 
%Growth Inhibition 
 
IC50 
 
R2 
 
0.1µM 
1.3342  
 
 
45.70 
 
 
 
0.9995 
 
1µM 
12.6079 
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33.8761 
 
100µM 
74.8578 
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Table No.5 TD2 
 
 
Concentration (µM) 
 
%Growth Inhibition 
 
IC50 
 
R2 
 
0.1µM 
 
1.0424 
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Table No.10 TD3 
 
Concentration (µM) 
 
%Growth Inhibition 
 
IC50 
 
R2 
 
0.1µM 
3.1895 
 
 
 
75.26 
 
 
 
0.9916 
 
1µM 
14.2646 
 
10µM 
23.6772 
 
100µM 
55.0587 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
0 20 40 60 80 100 120
%
 C
el
l I
nh
ib
iti
on
Concentarion in µM
 70 
 
Table No.11 TD4 
 
 
Concentration (µM) 
 
%Growth Inhibition 
 
IC50 
 
R2 
 
0.1µM 
1.4315 
 
 
 
92.36 
 
 
 
0.9916 
 
1µM 
19.6317 
 
10µM 
35.4864 
 
100µM 
63.8275 
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Table No.7 TD5 
 
 
Concentration (µM) 
 
%Growth Inhibition 
 
IC50 
 
R2 
 
0.1µM 
1.5342 
 
 
 
68.25 
 
 
 
0.9367 
 
1µM 
12.9079 
 
10µM 
30.9861 
 
100µM 
60.8578 
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Table No.9 TD6 
 
 
Concentration (µM) 
 
%Growth Inhibition 
 
IC50 
 
R2 
 
0.1µM 
1.2342 
 
 
 
48.60 
 
 
 
0.9916 
 
1µM 
12.3079 
 
10µM 
32.9861 
 
100µM 
73.8578 
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Table No.6 TD7 
 
 
Concentration (µM) 
 
%Growth Inhibition 
 
IC50 
 
R2 
 
0.1µM 3.4112 
 
 
 
>100 
 
 
 
0.9907 
 
1µM 13.7176 
 
10µM 33.8976 
 
100µM 
74.8578 
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CHAPTER– 5 
RESULTS AND DISCUSSION 
 
5.1. Chemical work: 
 The results of the present work are discussed under the following heads. 
 Scheme:2-(3-(4-(4-amino phenyl sulfonyl) phenyl)-4-oxo-2- (4-substituted-phenyl 
thiazolidin-5-yl) acetic acid. 
 5.1.1 Synthesis of 2-(3-(4-(4-aminophenylsulfonyl)phenyl)-4-oxo-2-(4-substituted-
phenylthiazolidin-5-yl) acetic acid.  
 Synthetic route depicted in scheme outline the chemistry part of the presentwork. 2-(3-
(4-(4-aminophenylsulfonyl)phenyl)-4-oxo-2-(4-substituted-phenylthiazolidin-5-yl) acetic 
acid (TD1-7) were obtained by the condensation of 4-(4-amino phenyl sulfonyl) 
benzenamine with substituted benzaldehydes in presence of dry dioxane, concentrated 
sulphuric acid and ethanol. The formation of the substituted thiazolidinone was confirmed by 
the presence of characteristic peaks in the IR spectra. It showed characteristic peaks at around 
3400 cm-1 for NH2 stretching and peak around 2900 cm-1 due to the presence of  N=CH 
stretching. The NMR spectrum of the compounds TD1-7 showed the characteristic peak 
around δ 2.70 ppm for CH3 group, δ 3.00 ppm for CH2 and δ 5.70 ppm for NCH and also 
shows multiplet in the range of δ 6.80-8.30 ppm owing to aromatic protons. The appearance 
of peak due to chlorine in IR spectra around 700 -800 cm-1 and formation M+2 peak in the 
mass spectra. Data from the elemental analyses and molecular ion recorded in the mass 
spectra further confirmed the assigned structure.  
5.2. Pharmacological Investigation 
         The anticancer screening of title compounds (TD1-7) were evaluated against human 
cervical cancer cell line (HeLa) by MTT assay method. In  this assay  the effective  ranges of 
75 
 
anticancer  activity  for compounds TD1-7 were in the concentration of 0.1, 1.0, 10, 100 µM 
respectively in the  human  cervical  cancer  cell line (HeLa).  Triplicate was maintained and 
the medium containing without samples were served as control. 
         TD1 (p-nitrophenyl) produced IC50 value 45.70 µM in case of the human cervical 
cancer cell line (HeLa). Relatively less value of  IC50 indicates the sample has more 
anticancer activity. The  compounds TD1 (p-nitro phenyl) had  shown  the  percentage  of  
cell inhibition  was 74.85 against  the  human  cervical  cancer  cell  line (HeLa) in  the 
highest concentration, which have p-nitrophenyl group in the thiazolidinone nucleus.    
 The result indicates that TD1 (p-nitrophenylgroup) showed a significant anticancer 
activity against the human cervical cancer cell line (HeLa), when compared to that control.  
       TD2 (dimethyl amino group) produced IC50 value 66.23 µM in case of the human 
cervical cancer cell line (HeLa). Relatively less value of IC50 indicates the sample has more 
anticancer activity. The  compound TD2 (dimethyl amino group) had  shown  the  percentage  
of  cell inhibition  was 52.89 against  the  human  cervical  cancer  cell  line  (HeLa) in  the 
highest concentration, which have dimethylamino group in the thiazolidinone nucleus.  
       The results indicate that TD2 (dimethyl amino group) showed a moderate anticancer 
activity against the human cervical cancer cell line (HeLa), when compared to that of control.  
 TD3 (methoxyl group) produced IC50 value 75.26µM in case of the human cervical 
cancer cell line (HeLa). Relatively less value of IC50 indicates the sample has more anticancer 
activity. The compound TD2 (methoxyl group) had shown the percentage of cell inhibition 
was 52.25 against the human cervical cancer cell line (HeLa), which have dimethyl amino 
group in the thiazolidinone nucleus.    
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 The results indicate that TD3 (methoxyl group) showed a less anticancer activity 
against the human cervical cancer cell line (HeLa), when compared to that of control. 
 TD4 (Hydroxyl group) produced IC50 value 92.36 µM in case of the human cervical 
cancer cell line (HeLa). Relatively less value of IC50 indicates the sample has more anticancer 
activity. The compound TD4 (Hydroxyl group) had  shown  the percentage of cell inhibition  
was 63.82 against  the  human  cervical  cancer  cell  line  (HeLa) in  the highest  
concentration, which have  imidazole group in  the  thiadiazole nucleus.  
       The results indicate that TD4 (Hydroxyl group) showed a moderate significant anticancer 
activity against the human cervical cancer cell line (HeLa), when compared to that of control. 
       TD5 (vinyl group) produced IC50 value 75.26 µM in case of the human cervical cancer 
cell line (HeLa). Relatively less value of IC50 indicates the sample has more anticancer 
activity.  The  compound TD5  (vinyl group) had  shown  the  percentage  of  cell inhibition  
was 55.05 against  the  human   cervical  cancer  cell  line  (HeLa) in  the highest 
concentration, which have vinyl group in the thiazolidinone nucleus.  
The results indicate that TD5 (vinyl group) showed a moderate significant anticancer 
activity against the human cervical cancer cell  line  (HeLa), when compared  to  that of 
control.  
TD6 (p-amino grp) producedIC50value 48.60 µM in case of  the  human  cervical 
cancer cell line (HeLa). Relatively high value of IC50 indicates the sample has more 
anticancer activity. The  compound TD6 (p-amino group) had  shown  the  percentage  of  
cell inhibition  was 73.85 against  the  human  cervical  cancer  cell  line  (HeLa) in  the 
highest concentration, which have p-amino group in the thiazolidinone nucleus.   
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The  results  indicates  that TD6 (p-amino group) showed  a good  significant 
anticancer activity against  the human cervical cancer cell  line  (HeLa), when compared  to  
that of control. 
TD7 (p-chloro group) produced IC50 value > 100 µM in  case  of  the  human  cervical 
cancer cell line (HeLa). Relatively high value of  IC50 indicates the sample has more and 
significant anticancer activity. The  compound TD7 (p-chloro group) had  shown  the  
percentage  of  cell inhibition  was 55.05 against  the  human  cervical  cancer  cell  line  
(HeLa) in  the highest concentration, which have p-chloro group in the thiadiazole nucleus.    
The  results  indicates  that TD7 (p-chloro group)  showed  a more significant 
anticancer activity against  the human cervical cancer cell  line  (HeLa), when compared  to  
that of control.   
The best mean  IC50 values were achieved with compound (TD3, TD4, TD5 and 
TD7) with slight difference among them. Title compounds (TD1-7) were found to exhibit 
mild to moderate anticancer activities in cell lines and the results were summarized below: 
 Compound TD1 (p-nitrophenyl group) shows less activity against the HeLa (IC50 – 
47.50) cancer cell lines.  
 Compound TD2 (dimethylamino group) shows moderate activity against the HeLa 
(IC50 – 66.23) cancer cell lines. 
 Compound TD3 (methoxyl group) shows high significant activity against the HeLa 
(IC50 72.56) cancer cell lines.    
 Compound TD4 (4-hydroxl group) shows more & potent significant against the HeLa 
(IC50 –92.36) cancer cell lines.  
 Compound TD5 (vinyl group) shows the moderate activity against the HeLa (IC50 – 
68.25) cancer cell lines.  
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 Compound TD6 (p-amino group) shows less significant activity against the HeLa (IC50 
–48.60) cancer cell lines.     
 Compound TD7 (p-chloro) shows very high and potent significant activity against the 
HeLa (IC50 > 100) cancer cell lines. 
  Among the test compounds, compound 3-(4-(4-aminophenylsulfonyl)phenyl)-2-(4-
chlorophenyl)-4-oxothiazolidin-5-yl) acetic acid (TD7) was found to be the most active agent 
which showed 74.85 percentage  of  cell inhibition against  the  human  cervical  cancer  cell  
line (HeLa) in  the highest concentration, which have p-chloro group in the thiazolidinone 
nucleus.  
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CHAPTER–6 
 
 
SUMMARY AND CONCLUSION 
 
 
In summary, a new series of 2-(3-(4-(4-aminophenylsulfonyl) phenyl)-4-oxo-2-(4-
substituted-phenyl thiazolidin-5-yl) acetic acid were synthesized. These title compounds 
containing seven different substituents at C-2 and C-3 were screened for their anticancer 
agents. Most of the test compounds were found to exhibit significant anticancer activity 
against the human cervical cancer cell line (HeLa) in the highest concentration. Among the 
substituents at C-2, p-chloro phenyl substituent and at C-5 4-amino phenyl sulfonyl 
substitutent showed maximum potency, while 4-methoxy phenyl, 4- hydroxy phenyl and  4- 
nitro phenyl substitutent showed equipotent activity but the dimethylaminophenyl, vinyl and 
4-amino phenyl substituent at C-2 exhibited least activity when compare to other substituents. 
The order of activity at C-2 is p-chloro phenyl ≥ 4- hydroxy phenyl ≥ 4-methoxy phenyl ≥ 4- 
nitro phenyl ≥ 4-amino phenyl ≥ dimethylaminophenyl ≥ vinyl substituents. 
 Among the test compounds, compound 3-(4-(4-aminophenylsulfonyl)phenyl)-2-(4-
chlorophenyl)-4-oxothiazolidin-5-yl) acetic acid (TD7) was found to be the most active agent 
which showed 74.85 percentage  of  cell inhibition against  the  human  cervical  cancer  cell  
line (HeLa) in  the highest concentration, which have p-chlorophenyl group in the 
thiazolidinone nucleus. 
Hence this molecule can be selected as a lead molecule of the present study for further 
exploitation.   
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CHAPTER- 7 
 
 
FUTURE PLAN OF WORK 
 
 
 
 
 
It may conclude that further beneficial pharmacophore modifications in the 
design of novel 2, 3-disubstituted thiazolidinone derivatives may be synthesized by 
designing novel ligands for therapeutic target by substituting different functional group 
and also examine with the help of NMR and X-ray which provide three dimensional 
frame works which can analyze structure activity data and can guide the design and 
synthesis of future potential therapeutic drugs towards other chronic disorders. 
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